drugset / Trial / NCT07501052

Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy

NCT07501052

Phase 2 Completed 33 enrolled Sam Chun Dang Pharm. Co. Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, multicenter study to evaluate clinical usability of a pre-filled syringe containing SCD411 in adult patients with neovascular Wet Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), or Diabetic Retinopathy (DR)

Timeline

Start
2026-05-13
Primary completion
2026-05-27
Completion
2026-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject SCD411 Unknown 2 mg Intravitreal